Abstract: The present invention relates to polynucleotides enabling the rapid, simple and specific detection of Group B Streptococcus highly-virulent ST-17 clones. The present invention also relates to the polypeptides encoded by the polynucleotides, as well as to antibodies directed or raised against the polypeptides. The present invention also relates to kits and methods for the specific detection of Group B Streptococcus highly-virulent ST-17 clones, using the polynucleotides, the polypeptides or the antibodies according to the invention.

Abstract: The invention relates to nucleic sequences derived from a human erythrovirus type V9, fragments of the sequences and their methods of use including applications as a diagnostic reagent and as immunogenic agent.

Abstract: A method for obtaining cell populations derived from the muscular tissue and their use for preparing cell therapy products includes culturing cells previously removed by biopsy from skeletal muscular tissues, identifying the different types of cells present at different stages of culture, selecting the culture stage on the basis of the required cell population and collecting the selected culture stage for preparing a cell therapy product. The invention also concerns cell populations derived from muscular tissue obtained by implementing the method whereof the dominant cell type is CD34+, CD15+ or CD56+ or Class 1+HLA, or comprises a doubly negative CD56?/CD15? cell type or may comprise more minority CD10+, Stro-1+ and CD 117+ cell types.

Abstract: The invention relates to a method for determining the amount of nucleic acid present in a sample, wherein:—a fluorophore is added to the sample,—fluorescence intensities emitted by the fluorophore at least two emission wavelengths in response to light stimulations at least two excitation wavelengths respectively are measured, and—the amount of nucleic acid present in the sample is deduced from the measured fluorescence intensities.

Abstract: A method for obtaining cell populations derived from the muscular tissue and their use for preparing cell therapy products includes culturing cells previously removed by biopsy from skeletal muscular tissues, identifying the different types of cells present at different stages of culture, selecting the culture stage on the basis of the required cell population and collecting the selected culture stage for preparing a cell therapy product. The invention also concerns cell populations derived from muscular tissue obtained by implementing the method whereof the dominant cell type is CD34+, CD15+ or CD56+ or Class 1+ HLA, or comprises a doubly negative CD56?/CD15? cell type or may comprise more minority CD10+, Stro-1+ and CD117+ cell types.

Abstract: Genotypic diagnosis of CADASIL for symptomatic or at risk individuals or fetuses belonging to a family suspected of being affected by CADASIL is carried out by detecting DNA polymorphisms genetically linked to the mutated gene responsible for CADASIL, these DNA polymorphisms being located in the genetic interval of the chromosome 19 flanked by the microsatellites D198221 and D19S215 and including these microsatellites.